Jane Street
NMRA icon

Jane Street’s Neumora Therapeutics NMRA Stock Holding History

Jane Street’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-209,200
Closed -$2.22M – 10228
2024
Q4 		$2.22M Buy
+209,200
New +$2.51M ﹤0.01% 3930

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Jane Street's NMRA Position: Q1 2026 in Review

Jane Street reduced its Neumora Therapeutics (NMRA) stake by 34% in Q1 2026, selling an estimated $988K and leaving 747,665 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #5699.

Jane Street first reported a position in NMRA in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.02M in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Jane Street held 747,665 shares of Neumora Therapeutics worth $1.46M as of Q1 2026.
  • Jane Street sold 381,307 Neumora Therapeutics shares in Q1 2026, an estimated $988K.
  • Neumora Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5699 holding.
  • Jane Street first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Jane Street's Neumora Therapeutics position peaked at $2.02M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.